- Home
- CBUS vs APLT Comparison
CBUS vs APLT Comparison
Compare CBUS & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBUS
- APLT
- Stock Information
- Founded
- CBUS 2010
- APLT 2016
- Country
- CBUS United States
- APLT United States
- Employees
- CBUS N/A
- APLT N/A
- Industry
- CBUS Agricultural Chemicals
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- CBUS Industrials
- APLT Health Care
- Exchange
- CBUS Nasdaq
- APLT Nasdaq
- Market Cap
- CBUS 65.3M
- APLT 52.9M
- IPO Year
- CBUS 2017
- APLT 2019
- Fundamental
- Price
- CBUS $1.55
- APLT $0.33
- Analyst Decision
- CBUS Strong Buy
- APLT Buy
- Analyst Count
- CBUS 3
- APLT 7
- Target Price
- CBUS $22.00
- APLT $6.10
- AVG Volume (30 Days)
- CBUS 927.1K
- APLT 2.3M
- Earning Date
- CBUS 08-07-2025
- APLT 08-06-2025
- Dividend Yield
- CBUS N/A
- APLT N/A
- EPS Growth
- CBUS N/A
- APLT N/A
- EPS
- CBUS N/A
- APLT N/A
- Revenue
- CBUS $4,751,000.00
- APLT $265,000.00
- Revenue This Year
- CBUS $32.97
- APLT $1,768.13
- Revenue Next Year
- CBUS $66.40
- APLT $292.85
- P/E Ratio
- CBUS N/A
- APLT N/A
- Revenue Growth
- CBUS 104.78
- APLT N/A
- 52 Week Low
- CBUS $1.38
- APLT $0.30
- 52 Week High
- CBUS $10.77
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- CBUS 42.57
- APLT 46.71
- Support Level
- CBUS $1.40
- APLT $0.30
- Resistance Level
- CBUS $1.67
- APLT $0.36
- Average True Range (ATR)
- CBUS 0.14
- APLT 0.03
- MACD
- CBUS 0.02
- APLT 0.00
- Stochastic Oscillator
- CBUS 62.07
- APLT 46.22
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.